Preventing bronchopulmonary dysplasia: new tools for an old challenge

• Type: Article in International Scientific Journal
• Date: 2019

Authors

Alvarez Fuente, M (Author) Other; Moreno, L (Author) Other; Mitchell, JA (Author) Other; Reiss, IK (Author) Other; Lopez, P (Author) Other; Elorza, D (Author) Other; Duijts, L (Author) Other; Avila Alvarez, A (Author) Other; Arruza, L (Author) Other; Ramirez Orellana, MR (Author) Other; Baraldi, E (Author) Other; Zaramella, P (Author) Other; Rueda, S (Author) Other; Gimeno Diaz de Atauri, AGD (Author) Other; Guimarães H (Author) FMUP; Rocha, G (Author) Other; Proenca, E (Author) Other; Thebaud, B (Author) Other; Jesus del Cerro, MJ (Author) Other

Journal

Title: Pediatric Research

Vol. 85

Pages: 432-441

ISSN: 0031-3998

Publisher: Springer Nature

Indexing

ISI Web of Knowledge - 26 Citations

Scopus - 30 Citations

Other information

Authenticus ID: P-00P-YQM

DOI: 10.1038/s41390-018-0228-0

Abstract (EN): Bronchopulmonary dysplasia (BPD) is the most prevalent chronic lung disease in infants and presents as a consequence of preterm birth. Due to the lack of effective preventive and treatment strategies, BPD currently represents a major therapeutic challenge that requires continued research efforts at the basic, translational, and clinical levels. However, not all very low birth weight premature babies develop BPD, which suggests that in addition to known gestational age and intrauterine and extrauterine risk factors, other unknown factors must be involved in this disease's development. One of the main goals in BPD research is the early prediction of very low birth weight infants who are at risk of developing BPD in order to initiate the adequate preventive strategies. Other benefits of determining the risk of BPD include providing prognostic information and stratifying infants for clinical trial enrollment. In this article, we describe new opportunities to address BPD's complex pathophysiology by identifying prognostic biomarkers and develop novel, complex in vitro human lung models in order to develop effective therapies. These therapies for protecting the immature lung from injury can be developed by taking advantage of recent scientific progress in -omics, 3D organoids, and regenerative medicine.

Language: English

Type (Professor's evaluation): Dissemination

No. of pages: 10